A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality
Since December 2019, coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has changed our lives. Elderly and those with comorbidities represent the vast majority of patients hospitalized with severe COVID-19 symptoms, including a...
Saved in:
| Main Authors: | Serge Camelo, Mathilde Latil, Sam Agus, Waly Dioh, Stanislas Veillet, René Lafont, Pierre J. Dilda |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2021.2006579 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modulation of the renin-angiotensin system against COVID-19: A path forward?
by: Serge Camelo, et al.
Published: (2025-05-01) -
An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters
by: Esther Föderl-Höbenreich, et al.
Published: (2025-04-01) -
Mrgprb2-dependent Mast Cell Activation Plays a Crucial Role in Acute ColitisSummary
by: Samuel Van Remoortel, et al.
Published: (2024-01-01) -
Dexamethasone has profound influence on the energy metabolism of porcine blood leukocytes and prevents the LPS-induced glycolytic switch
by: Wenjuan Ma, et al.
Published: (2025-02-01) -
Dexamethasone effects on the expression and content of glycosylated components of mouse brain tissue
by: S. D. Aladev, et al.
Published: (2023-04-01)